1,4-纳夫托金类型的化学结构-生物活性作为潜在的Aedes aegypti幼虫杀虫剂
Seong Jong Kim1, Md Imdadul H Khan2, Alden S Estep3
1Natural Products Utilization Research Unit, United States Department of Agriculture, Agricultural Research Service, University, USA.
Pest management science
|January 23, 2025
概括
在1,4-纳夫托金上进行替代,增强了对埃及甲虫的杀性活性. 有前途的化合物显示出对敏感和耐药的蚊子菌株的广泛疗效,有助于农药的开发.
科学领域:
- 药用化学 医学化学
- 有机化学 有机化学
- 矢量控制控制器 矢量控制器
背景情况:
- 1,4-纳夫托基诺对埃及白虫幼虫具有杀虫剂特性.
- 有限的结构-活性关系数据阻碍了纳夫托基诺因在农药开发中的优化.
- 这项研究侧重于2-基-1,4-纳夫托金及其衍生物,以阐明结构-活性关系.
研究的目的:
- 研究1,4-纳夫托金衍生物的结构-活性关系.
- 确定关键的结构修改,以增强对埃塞斯埃吉普蒂的杀性活动.
- 评估化合物与敏感和耐药的蚊子菌株进行对比.
主要方法:
- 在C-2,C-5和C-8位置进行修改的一系列1,4-纳夫托金的合成.
- 测试合成化合物的幼虫杀虫活性,以对抗埃及甲虫.
- 对对甲状腺敏感 (ORL1952) 和耐氨酸 (PR) 菌株的疗效进行比较分析.
主要成果:
- 在C-2位置的替代剂显著增加了蚊子幼虫的死亡率.
- 在C-2的2-基和2-甲基组的效果不如的效果.
- 化合物1和4a表现出强大的杀活性 (LC50值低至2.548 ppm) 对敏感和耐药菌株.
结论:
- 在C-2的替代对于提高幼虫杀虫疗效至关重要.
- 化合物1和4a显示出作为对抗Aedes aegypti的广谱剂的潜力.
- 这些发现支持进一步开发这些纳夫托金作为新型蚊虫控制剂.
相关概念视频
Physical Properties of Amines
3.0K
Amines with low molecular weight are usually gaseous at room temperature, while those with high molecular weight are liquid or solids in nature. Usually, low molecular weight amines have a rotten fish-like smell. Diamines typically have a pungent smell. For instance, cadaverine and putrescine, depicted in Figure 1, are two molecules responsible for decaying tissue.
3.0K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.1K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.1K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
515
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
515
Structure-Activity Relationships and Drug Design
493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493


